Feed IONS
IO

Ionis Pharmaceuticals

IONS · NASDAQ

$47.25 -7.64% (-$3.91)
1M -12.26%
Market Cap $8.55B
P/E Ratio -
Div. Yield -
ROE 110.84%
Piotroski F-Score Weak
2/9
Valuation
56 /100
Fair
EV/EBITDA 2.45x
P/S 9.78x
P/B 19.44x
Growth
75 /100
Growing
Rev. growth 17.14%
Book val. growth 5.13%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 98.16%
Net margin 64.64%
FCF margin 63.96%
Quality
4 /100
Poor
ROIC 20.37%
ROE 110.84%
Asset turnover 0.29x
Debt
50 /100
Moderate
Debt/Equity 5.50x
Current ratio 7.88x
Net debt/EBITDA 0.48x
Stability
47 /100
Moderate
Beta 0.42x
Rev. volatility 25.67%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o IONS
Online

O podjetju

Ionis Pharmaceuticals, Inc. is an American biotechnology company specializing in the development of RNA-targeted therapies for the treatment of various severe diseases. The company utilizes advanced antisense oligonucleotide (ASO) technology, which allows for targeted modification of RNA and regulation of gene expression, useful in treating conditions such as amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, and various genetic disorders. Ionis Pharmaceuticals is a leader in innovative treatment approaches, offering new possibilities for patients with previously untreatable diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Brett Monia

Employees

1,480

Headquarters

Carlsbad

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

50d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.